Boeing costs for 737 Max jump, profit falls by half

The company’s timetable for bringing back the Max after two crashes killed 346 people has repeatedly proved too optimistic.

SHARE Boeing costs for 737 Max jump, profit falls by half
Flags fly outside the main building of The Boeing Co.’s Oklahoma City facility in Oklahoma City.

Boeing’s third-quarter earnings fell 51% as it added another $900 million in costs for the troubled 737 Max.

AP

DALLAS — Boeing’s third-quarter earnings fell 51% as it added another $900 million in costs for the troubled 737 Max and deliveries of new planes tumbled from a year ago.

The Chicago company said Wednesday it has developed flight-control software and a pilot-training program for the Max, and it expects regulatory review of those fixes to begin in the fourth quarter.

Boeing eased concern that it might even temporarily shut down the Max assembly line near Seattle if the plane remains grounded. The company said it will raise 737 production from 42 a month to 57 a month by late next year.

The company’s timetable for bringing back the Max after two crashes killed 346 people has repeatedly proved too optimistic. A few weeks ago, CEO Dennis Muilenburg was predicting that the plane would be flying by about October.

Besides the crisis surrounding the 737 Max, which suffered its first crash a year ago this month, Boeing reported setbacks with two larger planes.

Boeing cited uncertainty around global trade in saying it will cut monthly production of the larger 787 jet from 14 a month to 12 for about two years, starting later this year. Last month, Muilenburg warned that trade tension with China — the company’s biggest foreign market — threatened sales of widebody planes like the 787.

And Boeing said it now aims to begin delivering the newest version of its big 777 airliner in early 2021. Problems with engines made by General Electric have delayed test flights for the 777X.

Boeing’s net income fell to $1.17 billion from $2.63 billion a year earlier. Per-share earnings were $1.45 after excluding nonrecurring items, which was far short of the $2.04 Wall Street was looking for, according to a poll by Zacks Investment Research.

Revenue was $19.98 billion, which was better than analysts expected but 21% lower than the same quarter in 2018. Deliveries of commercial planes plunged from 190 a year ago, to 62 in the third quarter as the worldwide grounding of the Max reached seven months.

Without cash coming in from deliveries of the 737, Boeing is hemorrhaging cash — free cash flow went from $4.1 billion a year ago to a negative $2.9 billion, and the company has taken on $5.5 billion in new debt.

On Tuesday, Boeing announced it was replacing the executive in charge of the commercial airplanes business, Kevin McAllister. The company didn’t give a reason for the move, but McAllister’s division has been rocked by the ongoing grounding of the Max, unexpected structural cracks in dozens of older 737s, a failed safety test for the 777X which is in development, and tepid sales of the 787 Dreamliner.

Canaccord Genuity analyst Ken Herbert said that while the Max gets all the attention, investors have grown increasingly worried about the other Boeing planes and other issues.

McAllister is the first high-level job casualty of the Max crisis, although earlier this month the company board stripped Muilenburg of his other role as chairman.

Company executives were scheduled to speak with industry analysts Wednesday to discuss what lies ahead for Boeing.

The Latest
Girls says the man is angry that she stood up for her mom in a disagreement about the couple’s sex and drinking habits.
Parent company Global Tetrahedron has big plans to diversify the satire news website’s revenue streams and bring back a print edition
Trout Unlimited’s Trout In The Classroom teaches young students about fish and the aquatic environment, capped by a day trip to get all wet.
From endorsing a new Bears’ stadium to revoking the subminimum wage, Johnson’s critics and allies examine where he and the city are going.
High doses become routine patient care even when they make patients so ill that they skip doses or stop taking the drugs. “There’s a gap in FDA’s authority that results in patients getting excess doses of a drug at excess costs,” says Dr. Mark Ratain.